Cancer Gene Therapy Market is projected to increase at a 10.1% CAGR from 2022 to 2032 | Get Insights FMI
[300+ Pages Report] As per Future Market Insights’ latest revised industry analysis, the global cancer gene therapy market is projected to expand at a 10.1% CAGR over the forecast period, with the market size reaching US$ 5.3 Bn in 2032.
Gene therapy is a field of medicine that aims to cure or greatly improve the treatment of diseases that have few or no treatment options. Advanced-stage cancer and hematological illnesses make up a large share of gene therapy candidates. In addition to this, gene therapy is frequently used to treat rare or inherited diseases.
While gene therapy research is still in its early stages, firms are increasingly investing in the technology. A handful of products have recently received approval outside of Canada or are in the final stages of clinical trials.
Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14971
Gene therapy is currently extremely expensive. Multi-stakeholder discussions about pricing and reimbursement management for these goods are required. To provide accessibility and quality of care, specialized manufacturing facilities, care centers, and doctors skilled to undertake specific procedures for such therapies are required.
The growth in the cancer gene therapy market is reliant on increasing awareness about health, the growing incidence of cancer, and the latest advancements in cancer gene therapy.
“Rising awareness regarding cancer gene therapy across emerging economies, along with favorable healthcare reimbursement plans in various countries will create opportunities for growth in the market over the forecast period,” says an FMI analyst.
Key Players :
- Merck KGaA
- Novartis AG
- AstraZeneca Plc.
- Crinetics Pharmaceuticals, Inc.
- EffRx Pharmaceuticals S.A.
- Euroscreen S.A.
- Vicore Pharma AB
- Bristol-Myers Squibb
- Cell Genesys Inc.
- Adaptimmune Therapeutics plc.
- Achieve Life Science Inc.
- BioCanCell Ltd.
- Genelux Corporation
- Advantagene Inc.,
- GenVec Inc.
- GlaxoSmithKline PLC
- Amgen Inc.
Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-question/rep-gb-14971
- Based on therapy, the oncolytic virotherapy segment accounted for about 3% of the total market share in 2021.
- In terms of indication, sales in the breast cancer segment are forecast to grow at a CAGR of 7% in the forecast period.
- By service provider, demand in the hospitals segment will grow at a 9.3% CAGR through 2032.
- The U.S. will dominate the North America cancer gene therapy market over the forecast period.
- China will emerge as a lucrative pocket, accounting for 32.3% of the East Asia cancer gene therapy market share over the assessment period.
- Demand in Germany is expected to increase at a 11.9% CAGR over the assessment period.
Acquisitions, partnerships, geographical recognition, and product launches are the key strategies adopted by leading players to increase the consumer base. For instance:
- In March 2022, Novartis and Carisma Therapeutics agreed to collaborate on the development of HER 2 targeted CAR-M cell therapy.
- A2 Biotherapeutics and Merck announced a collaboration in December 2020 to develop allogeneic cell therapy for solid tumor cancers.
Want More Insights
Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global cancer gene therapy market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the cancer gene therapy market segment based on therapy – (gene induced immunotherapy, oncolytic virotherapy, gene transfer, and others), by indication (breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer, and prostate cancer), by service provider (hospitals, clinical research laboratory, and oncology institutes), across seven major regions.
For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-14971
About Healthcare Division at Future Market Insights
Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business.
- Gene Induced Immunotherapy
- Oncolytic Virotherapy
- Gene Transfer
- Breast Cancer
- Ovarian Cancer
- Liver Cancer
- Pancreatic Cancer
- Lung Cancer
- Prostate Cancer
By Service Provider:
- Clinical Research Laboratory
- Oncology institutes
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
For Sales Enquiries: firstname.lastname@example.org
LinkedIn| Twitter| Blogs